Northpond Ventures, a private equity firm, led a $15m Series A round in QbDVision, a biotechnology company, with participation from S3 Ventures, Wanxiang Healthcare Investments, and Hudson Park Capital. "QbDVision is an exciting platform poised to drive digital transformation in the biopharmaceutical contract manufacturing segment. This product team has zeroed in on a critical gap in the solutions that the current innovation cycle is delivering across the drug development process. In just a few years, the industry's technology toolkit has expanded dramatically for drug discovery, clinical development, and commercial manufacturing – but not for CMC. QbDVision addresses this gap," Paxton Major, Northpond Ventures Senior Associate.